Efficacy and safety of bevacizumab plus capecitabine for metastatic colorectal cancer

Acta Academiae Medicinae Sinicae

Volumn 32, Issue 4, 2010, Pages 417-420

  Wu, Xiao Nan ^a   Zhao, Yun Bo ^a   Wu, Jian Yu ^a   Ding, Li ^a   Ai, Bin ^a   Li, Lin ^a   Zhou, Mei Zhen ^a  

^a BEIJING HOSPITAL   (China)

Author keywords

Bevacizumab; Capecitabine; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE;

ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SUBCUTANEOUS HEMORRHAGE; THROMBOEMBOLISM; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77957321285     PISSN: 1000503X     EISSN: None     Source Type: Journal    
DOI: 10.3881/j.issn.1000-503X.2010.04.012     Document Type: Article

References (13)

1. Wu JY, Wu XN, Ding L, et al. Phase I safety and pharmacokinetic study of bevacizumab (Avastin®) in Chinese patients with advanced cancer [J]. Chin Med J, 2010, 123(7): 901-906.
2. Folkman J. Tumor angiogenesis: therapeutic implications [J]. New Engl J Med, 1971, 285(21): 1182-1186.
3. Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients [J]. Eur J Cancer, 2000, 36(6): 748-753.
4. De Castro Junior G, Puglisi F, de Azambuja E, et al. Angiogenesis and cancer: a cross-talk between basic science and clinical trials (the "do ut des" paradigm) [J]. Crit Rev Oncol Hematol, 2006, 59(1):40-50.
5. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy [J]. Science, 2005, 307(5706): 58-62.
6. Wang Y, Fei D, Vanderlaan M, et al. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro [J]. Angiogenesis, 2004, 7(4): 335-345.
7. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules [J]. Nat Rev Clin Oncol, 2009, 6(9): 507-518.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, luorouracil, and leucovorin for metastatic colorectal cancer [J]. N Engl J Med, 2004, 350(23): 2335-2342.
9. Tebbutt NC, Wilson K. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study [J]. J Clin Oncol, 2010, 28(19): 3191-3198.
10. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study [J]. Ann Oncol, 2009, 20(11): 1842-1847.
11. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plusfluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2003, 21(1): 60-65.
12. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy [J]. Oncology, 2005, 69(Suppl 3): 25-33.